CEACAM5 and neoplasm: Tumor markers were re-evaluated before the second treatment cycle: CEA was 507.54 ng/mL, CA125 was 12.4 U/mL, and CA19–9 was 2.35 U/mL (Figure 1, July 28, 2021).